{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:46:34Z","timestamp":1754145994364,"version":"3.41.2"},"reference-count":13,"publisher":"Consortium of Multiple Sclerosis Centers","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>There has been an increasing number of reports describing B-cell\u2013associated disease activation in patients with multiple sclerosis after alemtuzumab treatment. Herein, 4.5 months after a first alemtuzumab infusion, a 33-year-old female patient had altered gait and vision loss associated with gadolinium enhancement of the optic nerves and chiasm on brain magnetic resonance imaging. The patient's blood showed normal B-cell counts concurrent with abnormally low T-cell counts. The patient stabilized after receiving steroids and prolonged plasma exchange without the use of rituximab. This case report adds to the growing body of literature of B-cell\u2013associated disease activation after alemtuzumab infusion and provides a therapeutic strategy to stabilize patients when rituximab is not readily available or if contraindications to its use exist.<\/jats:p>","DOI":"10.7224\/1537-2073.2018-030","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T15:28:24Z","timestamp":1536161304000},"page":"125-128","source":"Crossref","is-referenced-by-count":1,"title":["Stabilization Without Rituximab After Disease Activation in an Alemtuzumab-Treated Patient with Multiple Sclerosis and a Literature Overview"],"prefix":"10.7224","volume":"21","author":[{"given":"Chantal","family":"Kahovec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael C.","family":"Levin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4242","reference":[{"key":"2020060300340024300_i1537-2073-21-3-125-b1","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"2020060300340024300_i1537-2073-21-3-125-b2","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"2020060300340024300_i1537-2073-21-3-125-b3","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab","volume":"74","author":"Baker","year":"2017","journal-title":"JAMA Neurol"},{"key":"2020060300340024300_i1537-2073-21-3-125-b4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1474-4422(16)30382-9","article-title":"Severe B-cell\u2013mediated CNS disease secondary to alemtuzumab therapy","volume":"16","author":"Haghikia","year":"2017","journal-title":"Lancet Neurol"},{"key":"2020060300340024300_i1537-2073-21-3-125-b5","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1212\/WNL.0000000000004950","article-title":"Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis","volume":"90","author":"Wehrum","year":"2018","journal-title":"Neurology"},{"key":"2020060300340024300_i1537-2073-21-3-125-b6","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000320","article-title":"An observational study of alemtuzumab following fingolimod for multiple sclerosis","volume":"4","author":"Willis","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2020060300340024300_i1537-2073-21-3-125-b7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.msard.2017.10.014","article-title":"Management of MS-relapse during alemtuzumab therapy: is it really B-cell\u2013mediated?","volume":"19","author":"Schwenkenbecher","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"2020060300340024300_i1537-2073-21-3-125-b8","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1212\/WNL.0000000000003694","article-title":"Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab","volume":"88","author":"Barton","year":"2017","journal-title":"Neurology"},{"key":"2020060300340024300_i1537-2073-21-3-125-b9","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann Neurol"},{"key":"2020060300340024300_i1537-2073-21-3-125-b10","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1001\/jamaneurol.2017.4842","article-title":"Differences in the reponses to apheresis therapy of patients with 3 histopathologically classified immunopathological patterns of multiple sclerosis","volume":"75","author":"Stork","year":"2018","journal-title":"JAMA Neurol"},{"key":"2020060300340024300_i1537-2073-21-3-125-b11","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1046\/j.1526-0968.2001.00386.x","article-title":"Plasmapheresis affects T helper type-1\/T helper type-2 balance of circulating peripheral lymphocytes","volume":"5","author":"Goto","year":"2001","journal-title":"Ther Apher"},{"key":"2020060300340024300_i1537-2073-21-3-125-b12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/ajh.20342","article-title":"Effect of plasma exchange on cytokines measured by multianalyte bead array in thrombotic thrombocytopenic purpura","volume":"79","author":"Shariatmadar","year":"2005","journal-title":"Am J Hematol"},{"key":"2020060300340024300_i1537-2073-21-3-125-b13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aab4176","article-title":"Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy","volume":"7","author":"Li","year":"2015","journal-title":"Sci Transl Med"}],"container-title":["International Journal of MS Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/21\/3\/125\/2436138\/1537-2073_2018-030.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/21\/3\/125\/2436138\/1537-2073_2018-030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:11:59Z","timestamp":1752786719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijmsc.org\/view\/stabilization-without-rituximab-after-disease-activation-in-an-alemtuzumab-treated-patient-with-multiple-sclerosis-and-a-literature-overview"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.7224\/1537-2073.2018-030","relation":{},"ISSN":["1537-2073"],"issn-type":[{"type":"print","value":"1537-2073"}],"subject":[],"published":{"date-parts":[[2019,5,1]]}}}